Background: Conventional antidiabetic drugs are linked with a number of contraindications and untoward effects. The root decoction of L. has traditionally been used to treat diabetes. However, its safety and efficacy have not been scientifically authenticated yet. Hence, the study was conducted in mice to corroborate its antidiabetic potential and safety profile.
Methods: Using normoglycemic, oral glucose-loaded, and streptozotocin-induced diabetic mice models, the hypoglycemic and antihyperglycemic activities of 80% methanolic root extract were investigated. On streptozotocin-induced diabetic mice, the effect of the test extract on diabetic lipid profile and body weight was also investigated. Further, the in vitro -amylase inhibition activity was assessed.
Results: The test extract was safe at a limit test dose of 2 g/kg. Dose-dependent -amylase inhibition activity was seen with peak percentage inhibition of 75.95% at 700 g/mL. In normoglycemic mice, the plant extract showed statistically significant hypoglycemic activity at 200 and 400 mg/kg ( < 0.001) at 6 h and 4 and 6 h of treatment, respectively; in oral glucose-loaded mice, at both the test doses, the glucose level was also significantly dropped at 120 ( < 0.01) and 60 and 120 min ( < 0.001), respectively; whereas, in the third model, the test extract showed significant antihyperglycemic activity at 100 mg/kg ( < 0.05) on the 14 day and at 200 ( < 0.01) and 400 mg/kg ( < 0.001) on the 7 and 14 day of treatment. Similarly, following repeated administration of the test extract at 200 and 400 mg/kg, the body weight was significantly improved on the 14 day ( < 0.05) and on the 7 and 14 day ( < 0.01), respectively, while diabetic dyslipidemia after 14 days ( < 0.05).
Conclusion: The study revealed that the test extract showed promising antihyperglycemic and antihyperlipidemic activity. Thus, the findings back up its use in Ethiopian remedies for diabetes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239786 | PMC |
http://dx.doi.org/10.1155/2022/4454881 | DOI Listing |
BMC Health Serv Res
January 2025
Amref Health Africa in Ethiopia, EPI Technical Assistant at West Gondar Zonal Health Department, SLL Project, COVID-19 Vaccine, Gondar, Ethiopia.
Background: Ethiopian healthcare relies heavily on Health Extension Workers (HEWs), who deliver essential services to communities nationwide. By analyzing existing research, the authors explore how prevalent job satisfaction is and what factors affect it. This comprehensive analysis aims to improve HEW satisfaction through targeted interventions, ultimately leading to a more effective healthcare workforce and better health outcomes in Ethiopia.
View Article and Find Full Text PDFNat Commun
January 2025
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Gut microbiota disruptions after allogeneic hematopoietic cell transplantation (alloHCT) are associated with increased risk of acute graft-versus-host disease (aGVHD). We designed a randomized, double-blind placebo-controlled trial to test whether healthy-donor fecal microbiota transplantation (FMT) early after alloHCT reduces the incidence of severe aGVHD. Here, we report the results from the single-arm run-in phase which identified the best of 3 stool donors for the randomized phase.
View Article and Find Full Text PDFAcad Radiol
January 2025
Department of Radiology, Washington University School of Medicine, 510 S. Kingshighway Blvd, St. Louis, MO 63110 (S.I., M.A.T., M.I., C.S., R.L., A.H., R.L.W., T.J.F.). Electronic address:
Rationale And Objective: Conventional positron emission tomography (PET) respiratory gating utilizes a fraction of acquired PET counts (i.e., optimal gate [OG]), whereas elastic motion correction with deblurring (EMCD) utilizes all PET counts to reconstruct motion-corrected images without increasing image noise.
View Article and Find Full Text PDFBMJ Open
January 2025
Centre for Public Health, Institute of Clinical Sciences B, Royal Victoria Hospital, Queen's University Belfast School of Medicine, Dentistry and Biomedical Sciences, Belfast, UK.
Objectives: This study sheds light on the available global definitions, classifications, and criteria used for rare diseases (RDs), ultrarare diseases (URDs), orphan drugs (ODs) and ultraorphan drugs (UODs) and provides insights into the rationale behind these definitions.
Design: A systematic literature review was conducted to identify existing definitions and the criteria used to define RDs, ODs and their subtypes.
Data Sources: Searches were performed in the PubMed/Medline, Embase, Scopus and Web of Science (Science and Social Sciences Citation Index) databases covering articles published from 1985 to 2021.
BMJ Open
January 2025
Centre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Background: Worldwide, lung cancer (LC) is the second most frequent cancer and the leading cause of cancer related mortality. Low-dose CT (LDCT) screening reduced LC mortality by 20-24% in randomised trials of high-risk populations. A significant proportion of those screened have nodules detected that are found to be benign.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!